- Case Report
- Open Access
Long-term survival after surgical resection for recurrent hepatic and pulmonary metastases of intrahepatic cholangiocarcinoma: a case report
Surgical Case Reportsvolume 5, Article number: 135 (2019)
A few reports to date have described the effectiveness of surgical resection for recurrent intrahepatic cholangiocarcinoma (ICC). We report in this study a patient who achieved long-term survival after surgical resection for recurrent hepatic and pulmonary metastases of ICC.
A 62-year-old man was referred to our hospital for examination of a tumor in the left lobe of the liver. Computed tomography (CT) scans of the abdomen revealed a hypovascularized tumor, 30 mm in hepatic segment 2 (S2). The patient was diagnosed with a mass-forming type of ICC. A left lateral sectionectomy with regional lymph node dissection was performed. Histopathological examination showed moderately differentiated adenocarcinoma in the hepatic S2 with lymph node metastasis. There were two intrahepatic metastases around the main tumor. The pathological stage of the ICC was pT2pN1M0pStageIIIB. The patient did not receive adjuvant chemotherapy after surgery. Twelve months after surgery, liver lesions in S4/S8 and S7 were detected on CT scans. A partial hepatectomy was performed. The histopathological features were similar to those of the previous ICC. The patient did not receive adjuvant chemotherapy after the repeat hepatectomy. Four years and four months after this repeat hepatectomy, CT scans showed multiple nodes in S4 and S10 of the left lung and in S1 of the right lung. Wedge resection of the left upper lobe and sectionectomy in S10 of the left lung were performed. Histopathological findings of the resected lung nodules were compatible with metastatic ICC. The nodule in S1 of the right lung was too small to be diagnosed as metastasis; therefore, it was not resected. After pulmonary resection, the patient was treated with gemcitabine and cisplatin for 6 months. After chemotherapy, the size of the nodule in S1 increased gradually. One year and ten months after the pulmonary resection, we performed wedge resection of S1 of the right lung, and the histopathological findings were compatible with metastatic ICC. The patient is alive without evidence of disease 8 years after the initial surgery and 8 months after the last pulmonary resection.
ICC with poor prognostic factors can frequently recur; however, surgical resection for recurrent ICC might, for selected patients, enable long-term survival.
Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis. Surgical resection, which includes hepatectomy and regional lymph node dissection, is the only established curative therapy . Although curative resection is performed, the majority of patients develop ICC recurrence, especially intrahepatic recurrence. Several retrospective studies have documented that repeat hepatectomy for recurrent ICC provides survival benefits [2, 3]. This procedure has, therefore, been performed aggressively. Regarding pulmonary recurrence, there are a few reports that have documented the survival benefits of surgical resection for recurrent ICC. However, case reports of pulmonary metastasectomy are more limited than those of repeat hepatectomy. We report here a patient having undergone repeat hepatectomy and pulmonary resection with long-term survival.
A 62-year-old man was referred to our hospital for examination of a liver tumor in the hepatic left lobe. He had diabetes mellitus and prior hepatitis B virus infection. Laboratory test results for carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) were unremarkable. Computed tomography (CT) scans of the abdomen and gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) revealed a hypovascularized tumor, measuring 30 mm in hepatic segment 2 (S2), and no enlarged regional lymph nodes (Fig. 1). A liver biopsy was performed to analyze the tumor. A histopathological examination showed adenocarcinoma. On immunohistochemistry, the carcinoma cells were positive for cytokeratin 7 (CK7), CA 19-9, and EMA, and negative for CK20, α-fetoprotein, and thyroid transcription factor-1 (TTF-1). The patient was diagnosed with a mass forming (MF) type of ICC. A left lateral sectionectomy, with regional lymph node dissection along the proper, left and middle hepatic arteries and the upper branch of the left gastric artery, was performed. Histopathological examination showed moderately differentiated adenocarcinoma in hepatic S2, with one lymph node metastasis around the portal vein in the hepatoduodenal ligament and the minor branch of the portal vein invasion in the main tumor (Fig. 2); s0, n1, vp1, vv0, va0, and p0. There were two intrahepatic metastases in the same S2 around the main tumor. According to the eighth edition of the TNM staging system of the Union for International Cancer Control , the pathological stage of the ICC was pT2pN1M0pStageIIIB. The postoperative course was uneventful, and the patient was discharged on the tenth postoperative day. Although the adjuvant chemotherapy was recommended to him because there was a high possibility of recurrence of the carcinoma, he refused to undergo it.
Twelve months after surgery, liver lesions in S4/S8 and S7 were detected on CT scans (Fig. 3a, b). No other liver lesions were found using EOB-MRI. On positron emission tomography-computed tomography (PET-CT), abnormal fluorodeoxyglucose (FDG) uptake was observed only in hepatic tumors, and extrahepatic lesions were not detected (Fig. 3c). Neither CEA nor CA 19-9 was elevated. The patient wanted a second opinion on treatment other than surgery and chemotherapy. After observation for 3 months, the size of two recurrent liver tumors was slightly larger compared with that observed 3 months ago. However, without developing any other lesions, he underwent a partial hepatectomy for each lesion (Fig. 4a, d). A pathological examination of both resected tumors revealed moderately differentiated adenocarcinoma in the center of the tumors, which was similar to that of previous ICC (Fig. 4b, e). At the margin of the tumors, poorly differentiated adenocarcinoma was detected (Fig. 4c, f). On immunohistochemistry, the carcinoma cells were positive for CK 7 and negative for CK 20 and TTF-1. Histopathological features were similar to those of the previous ICC; therefore, the patient was diagnosed with recurrence of ICC. He was discharged on the seventh postoperative day. Although the adjuvant chemotherapy was repeatedly recommended to him, he refused to undergo the therapy after the repeat hepatectomy. Four years and four months after the repeat hepatectomy, CT scans showed multiple nodes in S4 and S10 of the left lung and in S1 of the right lung (Fig. 5a–c). On PET-CT, FDG uptake was observed only in S4 of the left lung (Fig. 5d–f). After observation for 3 months, the size and number of tumors did not change. Therefore, wedge resection of the left upper lobe and sectionectomy of S10 of the left lung were performed. The histopathological findings of the resected lung nodules were compatible with metastatic ICC (Fig. 6a). On immunohistochemistry, the carcinoma cells were positive for CK 7 and negative for CK 20 and TTF-1 (Fig. 6b–d). The nodule noted in S1 of the right lung was too small to be diagnosed for metastasis; therefore, it was not resected. After pulmonary resection, He was treated with gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) which were infused on day 1 and day 8. This regimen was repeated at 21-day intervals for 6 months. After chemotherapy, the size of the nodule in S1 of the right lung increased gradually. One year and ten months after the pulmonary resection, we confirmed that there were no other metastatic lesions and we performed a wedge resection of S1 of the right lung. Histopathological findings were compatible with metastatic ICC. On immunohistochemistry, the carcinoma cells were positive for CK 7 and negative for CK 20 and TTF-1. The patient is alive without evidence of disease 8 years after the initial surgery and 8 months after the last pulmonary resection.
The 5-year overall survival (OS) rate of ICC after curative intent surgery was reported to be only 15–40% . The risk factors for ICC recurrence after surgery include multiple tumors, vascular invasion, and lymph node metastasis [1, 6]. The survival benefits of adjuvant chemotherapy and chemoradiotherapy remain controversial. Five randomized clinical studies of adjuvant chemotherapy in patients with biliary tract cancer are currently ongoing, and three studies have recently been published [7,8,9]. For intrahepatic cholangiocarcinoma, several retrospective studies have evaluated the effect of adjuvant chemotherapy. Specifically, Reames et al.  in their study reported that adjuvant therapy was associated with a survival benefit in patients with advanced T stage (T2/3/4) (5-year OS: 37% vs. 30%; p = 0.006), periductal growth type (PI), or PI + MF subtype (5-year OS: 37% vs. 8%; p < 0.001) and lymph node metastasis (5-year OS: 18.3% vs. 12%; p = 0.050). Miura et al.  similarly described a survival benefit of adjuvant chemotherapy in patients with N1 disease (median OS: 19.8 vs. 10.7 months; p < 0.001), T3/4 tumors (median OS: 21.3 vs. 15.6 months, p < 0.001), and R1/R2 surgical resection (median OS: 29.5 vs. 11.6 months, p = 0.006). Our patient had several risk factors, such as multiple intrahepatic lesions, lymph node metastases, and vascular invasion, for recurrence of ICC after surgery, and he was recommended for adjuvant chemotherapy. However, the patient rejected adjuvant chemotherapy and was carefully monitored.
The resection of recurrent ICC demands challenging. Recently, repeat hepatectomy for recurrent ICC has been documented and has provided survival benefits [2, 3]. The median survival time after surgery for recurrent ICC was 10–66.6 months. Although the majority of the research has documented a small number of patients, Si et al.  in their study reported the survival outcome of 72 patients who underwent R0 repeat hepatic resection for recurrent ICC. The median time to recurrence was 13.6 months, and the median survival time was 45.1 months. The independent risk factors for overall survival were indicated as follows: recurrent tumor > 3 cm; multiple recurrent nodules; cirrhosis; and time to recurrence (TTR) < 1 year. In our patient, because he had risk factors of poor prognosis, such as multiple recurrent tumors and short TTR, he was observed for 3 months before repeat hepatectomy was performed and no other lesions were confirmed.
There have been a few reports to date of resection procedures for recurrent ICC, other than hepatectomy. Pulmonary resection for recurrent ICC has been described in several case reports , and there have additionally been few cases in small-sample studies published in English [13,14,15] (Table 1). There were eight cases with pulmonary resection for recurrent ICC, including seven reported cases and the present case. Two cases, including ours, had repeat pulmonary resection. The initial disease-free survival period was over 12 months in all patient cases except for one case, and survival period after recurrence was more than 60 months in five patient cases. The author previously reported that surgery for pulmonary metastases from cholangiocarcinoma should be considered in patients with a longer initial disease-free interval . In our patient, repeat pulmonary resection for recurrent ICC was performed after a sufficient observation period. In particular, the slow-growing lesion of S1 of the right lung was resected 1 year and 10 months after it was identified, with confirmation of no other additional lesions.
Our patient had several poor prognostic factors, and he did not receive adjuvant chemotherapy after the initial surgery. By performing repeat hepatectomy and pulmonary resection for recurrent ICC at the appropriate time after careful follow-up, a favorable outcome was conferred on the patient. Surgical resection for recurrent ICC might contribute toward long-term survival.
Availability of data and materials
Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.
- CA 19-9:
Carbohydrate antigen 19-9
Gadoxetic acid-enhanced magnetic resonance imaging
Mass forming type
Positron emission tomography-computed tomography
Periductal growth type
Thyroid transcription factor-1
Time to recurrence
Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–89.
Souche R, Addeo P, Oussoultzoglou E, Herrero A, Rosso E, Navarro F, et al. First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma. Am J Surg. 2016;212:221–9.
Si A, Li J, Xing X, Lei Z, Xia Y, Yan Z, et al. Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: Factors associated with long-term outcomes. Surgery. 2017;161:897–908.
Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours: Wiley-Blackwell; 2017.
Shimada K, Sano T, Nara S, Esaki M, Sakamoto Y, Kosuge T, et al. Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement. Surgery. 2009;145:411–6.
de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140–5.
Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. J Clin Oncol. 2019:Jco1800050.
Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192–202.
Primrose JN, Fox R, Palmer DH, Prasad R, Mirza D, Anthoney DA. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. J Clin Oncol. 2017;35:Abstrract 4006.
Reames BN, Bagante F, Ejaz A, Spolverato G, Ruzzenente A, Weiss M, et al. Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. HPB (Oxford). 2017;19:901–9.
Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, et al. Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2015;22:3716–23.
Morise Z, Sugioka A, Hoshimoto S, Kato T, Tanahashi Y, Ikeda M, et al. Patient with advanced intrahepatic cholangiocarcinoma with long-term survival successfully treated with a combination of surgery and chemotherapy. J Hepatobiliary Pancreat Surg. 2008;15:545–8.
Saiura A, Yamamoto J, Kokudo N, Koga R, Seki M, Hiki N, et al. Intrahepatic cholangiocarcinoma: analysis of 44 consecutive resected cases including 5 cases with repeat resections. Am J Surg. 2011;201:203–8.
Park HM, Yun SP, Lee EC, Lee SD, Han SS, Kim SH, et al. Outcomes for Patients with Recurrent Intrahepatic Cholangiocarcinoma After Surgery. Ann Surg Oncol. 2016;23:4392–400.
Ohira M, Kobayashi T, Hashimoto M, Tazawa H, Abe T, Oshita A, et al. Prognostic factors in patients with recurrent intrahepatic cholangiocarcinoma after curative resection: a retrospective cohort study. Int J Surg. 2018;54:156–62.
Yamada M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Pulmonary metastasis after resection of cholangiocarcinoma: incidence, resectability, and survival. World J Surg. 2017;41:1550–7.
We would like to thank enago (https://www.enago.jp) for English language editing.
Ethics approval and consent to participate
The case report was approved by the Human Research Review Committee of Kasugai Municipal Hospital.
Consent for publication
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.